title: The effect of adenosine A(2A) receptor antagonists on hydroxyl radical, dopamine, and glutamate in the striatum of rats with altered function of VMAT2.
abstract: It has been shown that a decreased vesicular monoamine transporter (VMAT2) function and the disruption of dopamine (DA) storage is an early contributor to oxidative damage of dopamine neurons in Parkinson's disease (PD). In our previous study, we demonstrated that adenosine A(2A) receptor antagonists suppressed oxidative stress in 6-hydroxydopamine-treated rats suggesting that this effect may account for neuroprotective properties of drugs. In the present study, rats were injected with reserpine (10 mg/kg sc) and 18 h later the effect of the adenosine A(2A) receptor antagonists 8-(3-chlorostyryl)caffeine (CSC) and 4-(2-[7-amino-2-(2-furyl)[1,2,4]triazolo[2,3-a][1,3,5]triazin-5-ylamino]ethyl)phenol (ZM 241385) on extracellular DA, glutamate and hydroxyl radical formation was studied in the rat striatum using in vivo microdialysis. By disrupting VMAT2 function, reserpine depleted DA stores, and increased glutamate and hydroxyl radical levels in the rat striatum. CSC (1 mg/kg) but not ZM 241385 (3 mg/kg) increased extracellular DA level and production of hydroxyl radical in reserpinised rats. Both antagonists decreased the reserpine-induced increase in extracellular glutamate. L-3,4-Dihydroxyphenylalanine (L-DOPA) (25 mg/kg) significantly enhanced extracellular DA, had no effect on reserpine-induced hydroxyl radical production and decreased extracellular glutamate concentration. CSC but not ZM 241385 given jointly with L-DOPA increased the effect of L-DOPA on extracellular DA and augmented the reserpine-induced hydroxyl radical production. CSC and ZM 241385 did not influence extracellular glutamate level, which was decreased by L-DOPA. It seems that by decreasing the MAO-dependent DA metabolism rate, CSC raised cytosolic DA and by DA autoxidation, it induced hydroxyl radical overproduction. Thus, the methylxanthine A(2A) receptor antagonists bearing properties of MAO-B inhibitor, like CSC, may cause a risk of oxidative stress resulting from dysfunctional DA storage mechanism in early PD.
authors.affiliation: Institute of Pharmacology, Polish Academy of Sciences, 31-343 Kraków, 12 Smętna Street, Kraków, Poland. nfgolemb@cyf-kr.edu.pl
authors.forename: Krystyna
authors.initials: K
authors.lastname: Gołembiowska
authors.forename: Anna
authors.initials: A
authors.lastname: Dziubina
mesh_terms: D015102:3,4-Dihydroxyphenylacetic Acid / Q000378:metabolism; D058917:Adenosine A2 Receptor Antagonists / Q000494:pharmacology*; D018759:Adrenergic Uptake Inhibitors / Q000633:toxicity; D000818:Animals; D002110:Caffeine / Q000031:analogs & derivatives / Q000494:pharmacology; D003342:Corpus Striatum / Q000187:drug effects / Q000378:metabolism*; D004298:Dopamine / Q000378:metabolism*; D015259:Dopamine Agents / Q000633:toxicity; D005110:Extracellular Space / Q000187:drug effects / Q000378:metabolism; D018698:Glutamic Acid / Q000378:metabolism*; D006719:Homovanillic Acid / Q000378:metabolism; D017665:Hydroxyl Radical / Q000378:metabolism*; D007980:Levodopa / Q000633:toxicity; D008297:Male; D017551:Microdialysis; D018384:Oxidative Stress / Q000187:drug effects; D051381:Rats; D017208:Rats, Wistar; D012110:Reserpine / Q000633:toxicity; D014227:Triazines / Q000494:pharmacology; D014230:Triazoles / Q000494:pharmacology; D050493:Vesicular Monoamine Transport Proteins / Q000235:genetics / Q000502:physiology*
chemical_list: D058917:Adenosine A2 Receptor Antagonists; D018759:Adrenergic Uptake Inhibitors; D015259:Dopamine Agents; C493454:Slc18a2 protein, rat; D014227:Triazines; D014230:Triazoles; D050493:Vesicular Monoamine Transport Proteins; C097270:ZM 241385; D015102:3,4-Dihydroxyphenylacetic Acid; C081320:8-(3-chlorostyryl)caffeine; D017665:Hydroxyl Radical; D002110:Caffeine; D018698:Glutamic Acid; D007980:Levodopa; D012110:Reserpine; D004298:Dopamine; D006719:Homovanillic Acid